Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Primary Prevention of Sudden Cardiac Death With Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Causes of Mortality in the Marfan Syndrome(from a Nationwide Register Study)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Partial Oral Therapy for Osteomyelitis and Endocarditis. Reply

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. In-hospital metabolite changes in infective endocarditis-a longitudinal 1H NMR-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Clinical implications of electrocardiographic bundle branch block in primary care

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Repeatability and Reproducibility of Neonatal Echocardiography: The Copenhagen Baby Heart Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Implantable cardioverter-defibrillator (ICD) therapy remains a corner stone of sudden cardiac death (SCD) prevention in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). We aimed to assess predictors of appropriate ICD therapies in the Scandinavian cohort of ARVC patients who received ICD for primary prevention of SCD. Study group comprised of 79 definite ARVC patients by 2010 Task Force criteria (60% male, age at ICD implant 39 ± 14 years) who were enrolled in the Nordic ARVC Registry and received an ICD for primary SCD prevention. The primary end point of appropriate ICD shock or death from any cause was assessed and compared with 137 definite ARVC patients who received ICD for secondary SCD prevention (74% male, age at ICD implant 42 ± 15 years). In the study group, 38% were ≤35 years of age at baseline, 25% had nonsustained ventricular tachycardia, and 29% had syncope at baseline. Major repolarization abnormality (hazard ratio = 4.00, 95% confidence interval 1.30 to 12.30, p = 0.015) and age ≤35 years (hazard ratio = 4.21, 95% confidence interval 1.49 to 11.85, p = 0.001) independently predicted the primary end point. The outcome did not differ between the primary prevention patients with either of these risk factors and the secondary prevention cohort (2% to 4% annual event rate) whereas patients without risk factors did not have any appropriate ICD shocks during follow-up. In conclusion, young age at ARVC diagnosis and major repolarization abnormality independently predict ICD shocks or death in the primary prevention ICD recipients and associated with the event rate similar to the one observed in the secondary prevention cohort. Our data indicate the benefit of ICD for primary prevention in patients with any of these risk factors.

OriginalsprogEngelsk
TidsskriftThe American journal of cardiology
Vol/bind123
Udgave nummer7
Sider (fra-til)1156-1162
Antal sider7
ISSN0002-9149
DOI
StatusUdgivet - 1 apr. 2019

Bibliografisk note

Copyright © 2019 Elsevier Inc. All rights reserved.

ID: 56978950